CAR - T细胞在实体癌和血液癌中的作用：相同但不同

IF 10 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2024-12-03 DOI:10.1158/1078-0432.ccr-24-3688

Sebastian Kobold

引用次数: 0

摘要

最近的一项I期临床研究测试了抗ror1 CAR - T细胞在CLL、NSCLC和TNBC患者中的应用。该产品可以安全使用，并且在CLL中具有活性，但在NSCLC和TNBC中则不那么有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

RORing CAR T cells in solid and hematological cancers: same but different

A recent phase I clinical study tested anti-ROR1 CAR T cells in patients with CLL, NSCLC, and TNBC. The product could be safely administered and had activity in CLL but less so in NSCLC and TNBC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.